Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial
- PMID: 20571015
- DOI: 10.1001/jama.2010.840
Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial
Abstract
Context: Blood homocysteine levels are positively associated with cardiovascular disease, but it is uncertain whether the association is causal.
Objective: To assess the effects of reducing homocysteine levels with folic acid and vitamin B(12) on vascular and nonvascular outcomes.
Design, setting, and patients: Double-blind randomized controlled trial of 12,064 survivors of myocardial infarction in secondary care hospitals in the United Kingdom between 1998 and 2008.
Interventions: 2 mg folic acid plus 1 mg vitamin B(12) daily vs matching placebo.
Main outcome measures: First major vascular event, defined as major coronary event (coronary death, myocardial infarction, or coronary revascularization), fatal or nonfatal stroke, or noncoronary revascularization.
Results: Allocation to the study vitamins reduced homocysteine by a mean of 3.8 micromol/L (28%). During 6.7 years of follow-up, major vascular events occurred in 1537 of 6033 participants (25.5%) allocated folic acid plus vitamin B(12) vs 1493 of 6031 participants (24.8%) allocated placebo (risk ratio [RR], 1.04; 95% confidence interval [CI], 0.97-1.12; P = .28). There were no apparent effects on major coronary events (vitamins, 1229 [20.4%], vs placebo, 1185 [19.6%]; RR, 1.05; 95% CI, 0.97-1.13), stroke (vitamins, 269 [4.5%], vs placebo, 265 [4.4%]; RR, 1.02; 95% CI, 0.86-1.21), or noncoronary revascularizations (vitamins, 178 [3.0%], vs placebo, 152 [2.5%]; RR, 1.18; 95% CI, 0.95-1.46). Nor were there significant differences in the numbers of deaths attributed to vascular causes (vitamins, 578 [9.6%], vs placebo, 559 [9.3%]) or nonvascular causes (vitamins, 405 [6.7%], vs placebo, 392 [6.5%]) or in the incidence of any cancer (vitamins, 678 [11.2%], vs placebo, 639 [10.6%]).
Conclusion: Substantial long-term reductions in blood homocysteine levels with folic acid and vitamin B(12) supplementation did not have beneficial effects on vascular outcomes but were also not associated with adverse effects on cancer incidence.
Trial registration: isrctn.org Identifier: ISRCTN74348595.
Comment in
-
Effects of folic acid plus vitamin B12 vs placebo in myocardial infarction survivors.JAMA. 2010 Oct 27;304(16):1783; author reply 1783-4. doi: 10.1001/jama.2010.1473. JAMA. 2010. PMID: 20978254 No abstract available.
-
Large placebo-controlled RCT in myocardial infarction survivors finds that daily folic acid and vitamin B12 have no effect on risk of major vascular event.Evid Based Med. 2011 Feb;16(1):12-3. doi: 10.1136/ebm1131. Epub 2010 Nov 16. Evid Based Med. 2011. PMID: 21081627 No abstract available.
Similar articles
-
Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial.JAMA. 2008 May 7;299(17):2027-36. doi: 10.1001/jama.299.17.2027. JAMA. 2008. PMID: 18460663 Free PMC article. Clinical Trial.
-
Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial.JAMA. 2007 Sep 12;298(10):1163-70. doi: 10.1001/jama.298.10.1163. JAMA. 2007. PMID: 17848650 Clinical Trial.
-
Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial.JAMA. 2008 Aug 20;300(7):795-804. doi: 10.1001/jama.300.7.795. JAMA. 2008. PMID: 18714059 Clinical Trial.
-
Homocysteine-lowering interventions for preventing cardiovascular events.Cochrane Database Syst Rev. 2017 Aug 17;8(8):CD006612. doi: 10.1002/14651858.CD006612.pub5. Cochrane Database Syst Rev. 2017. PMID: 28816346 Free PMC article. Review.
-
Interventions for lowering plasma homocysteine levels in dialysis patients.Cochrane Database Syst Rev. 2016 May 31;2016(5):CD004683. doi: 10.1002/14651858.CD004683.pub4. Cochrane Database Syst Rev. 2016. PMID: 27243372 Free PMC article. Review.
Cited by
-
Association between serum uric acid and homocysteine levels among adults in the United States: a cross-sectional study.BMC Cardiovasc Disord. 2023 Dec 8;23(1):599. doi: 10.1186/s12872-023-03586-0. BMC Cardiovasc Disord. 2023. PMID: 38066416 Free PMC article.
-
Intakes of folate, vitamin B6, and vitamin B12 and cardiovascular disease risk: a national population-based cross-sectional study.Front Cardiovasc Med. 2023 Nov 14;10:1237103. doi: 10.3389/fcvm.2023.1237103. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 38034370 Free PMC article.
-
Elevated Maternal Folate Status and Changes in Maternal Prolactin, Placental Lactogen and Placental Growth Hormone Following Folic Acid Food Fortification: Evidence from Two Prospective Pregnancy Cohorts.Nutrients. 2023 Mar 23;15(7):1553. doi: 10.3390/nu15071553. Nutrients. 2023. PMID: 37049394 Free PMC article.
-
Non-linear associations of serum and red blood cell folate with risk of cardiovascular and all-cause mortality in hypertensive adults.Hypertens Res. 2023 Jun;46(6):1504-1515. doi: 10.1038/s41440-023-01249-3. Epub 2023 Mar 10. Hypertens Res. 2023. PMID: 36899181
-
Nonlinear associations of serum cobalamin with risk of all-cause and cardiovascular mortality in hypertensive adults.Hypertens Res. 2023 May;46(5):1276-1286. doi: 10.1038/s41440-023-01218-w. Epub 2023 Feb 20. Hypertens Res. 2023. PMID: 36805030
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical